PRESS RELEASE published on 10/01/2025 at 17:49, 1 year ago HBM Healthcare Investments reports strong quarterly results – NAV rises by 16.4 per cent in the second quarter of the 2025/2026 financial year HBM Healthcare Investments reports a 16.4% increase in NAV in the second quarter of the 2025/2026 financial year, expects positive momentum from investments in private and listed companies Financial Results HBM Healthcare Investments Investment Performance NAV Increase Clinical Trial Results
PRESS RELEASE published on 10/01/2025 at 17:47, 1 year ago Key Figures 30.09.2025 HBM Healthcare Investments AG reports key performance figures as of 30.09.2025 in CHF. NAV at 251.78 CHF, Share Price at 180.80 CHF, Total Net Assets 1'682 million CHF HBM Healthcare Investments AG Key Figures CHF Performance Figures 30.09.2025
BRIEF published on 09/29/2025 at 10:39, 1 year 1 month ago Genmab to Acquire Merus for USD 8 Billion Acquisition Investment Oncology Genmab Merus
PRESS RELEASE published on 09/29/2025 at 10:34, 1 year 1 month ago Genmab to Acquire HBM Portfolio Company Merus for USD 8 billion in Cash Genmab to acquire HBM portfolio company Merus for USD 8 billion in cash. Merus is known for its innovative oncology therapies. The transaction with Genmab represents a 41% premium on the closing price Acquisition Oncology HBM Healthcare Genmab Merus
BRIEF published on 09/16/2025 at 17:52, 1 year 1 month ago HBM Healthcare Investments AG Reports Modest Growth in September 2025 Financial Results Net Asset Value Investment Performance Share Price HBM Healthcare
PRESS RELEASE published on 09/16/2025 at 17:47, 1 year 1 month ago Key Figures 15.09.2025 HBM Healthcare Investments AG reports key figures for 15.09.2025 in CHF. NAV at 245.43, Share Price at 178.00, and Total Net Assets at 1,641 million. Performance percentages shown Performance HBM Healthcare Investments AG Key Figures CHF 15.09.2025
BRIEF published on 09/10/2025 at 08:40, 1 year 1 month ago Swixx BioPharma and Lundbeck Forge Multi-Regional CNS Partnership Emerging Markets Swixx BioPharma Healthcare Investments Lundbeck CNS Partnership
PRESS RELEASE published on 09/10/2025 at 08:35, 1 year 1 month ago HBM Portfolio Company Swixx BioPharma and Lundbeck Sign Multi-Regional CNS Partnership HBM Healthcare Investments announces partnership between Swixx BioPharma, Lundbeck for CNS therapies in South-East Europe, Turkey and Latin America Partnership HBM Healthcare Investments CNS Therapies Swixx BioPharma Lundbeck
BRIEF published on 09/01/2025 at 17:52, 1 year 1 month ago HBM Healthcare Investments AG Reports August 2025 Key Figures Performance Share Price NAV Swiss Exchange HBM Healthcare
PRESS RELEASE published on 09/01/2025 at 17:47, 1 year 1 month ago Key Figures 31.08.2025 HBM Healthcare Investments AG reports key financial figures for August 2025, with a NAV of 240.62 CHF and Total Net Assets of 1,610 million CHF. Share price increased by 4.0% HBM Healthcare Investments Financial Figures Share Price NAV August 2025
Published on 10/29/2026 at 22:01, 7 hours 59 minutes ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended September 30, 2026
Published on 10/29/2026 at 21:30, 8 hours 30 minutes ago Shelfie Announces Amendments to Previously Announced Acquisition of Aspect
Published on 10/29/2026 at 18:30, 11 hours 30 minutes ago Kidoz Inc. Appoints Derek Sentner as Chief Revenue Officer
Published on 10/29/2026 at 16:05, 13 hours 55 minutes ago SouthGobi Announces Date of Special Meeting of Shareholders and The Record Date
Published on 10/29/2026 at 22:25, 7 hours 35 minutes ago SFC Energy continues strong, profitable growth in the first nine months of 2026 – preliminary figures – earnings guidance raised again
Published on 10/29/2026 at 22:21, 7 hours 39 minutes ago EQS-Adhoc: SFC Energy AG raises full-year 2026 earnings guidance again
Published on 10/29/2026 at 21:29, 8 hours 31 minutes ago 2CRSi SA: Publication of the consolidated annual results and the 2025-2026 Annual Financial Report postponed to 30 October 2026
Published on 10/29/2026 at 21:20, 8 hours 40 minutes ago 2CRSi SA: 2CRSi publishes the conclusions of the independent expert appointed following the Grizzly Research report and provides clarifications on several previous communications
Published on 10/29/2026 at 20:13, 9 hours 47 minutes ago Interim individual financial statements of Sirma Group JSC for the period ending on September 30, 2026
Published on 10/29/2026 at 18:02, 11 hours 58 minutes ago TF1 9M 2026 results - Consolidated financial statements and appendix
Published on 10/29/2026 at 18:00, 12 hours ago GUILLEMOT CORPORATION: THIRD-QUARTER 2026 TURNOVER / Successful new product launches and acceleration of international commercial partnerships
Published on 10/29/2026 at 17:45, 12 hours 15 minutes ago ENGIE commissions 450 MW of solar capacity in India
